Alkermes plc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Alkermes plc. (ALKS) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax of -$24.00 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-10-23.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax · last filed 2019-10-23
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2019-09-30 was -$24.00K, a 107.64% decline year-over-year.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2019-06-30 was $896.00K, a 501.34% increase year-over-year.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2019-03-31 was $770.00K.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for the quarter ending 2018-09-30 was $314.00K.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2018 was $512.00K.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2017 was -$518.00K, a 199.42% decline from fiscal 2016.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2016 was $521.00K.
- Alkermes plc. oci, debt securities, available-for-sale, gain (loss), after adjustment and tax for fiscal 2015 was -$659.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$24.00K 10-Q · filed 2019-10-23 | $872.00K derived: sum of 2 quarters · filed 2019-10-23 | $1.64M derived: sum of 3 quarters · filed 2019-10-23 | |
| 2019-06-30 | $896.00K 10-Q · filed 2019-10-23 | $1.67M derived: sum of 2 quarters · filed 2019-10-23 | ||
| 2019-03-31 | $770.00K 10-Q · filed 2019-10-23 | |||
| 2018-12-31 | $512.00K 10-K · filed 2019-02-15 | |||
| 2018-09-30 | $314.00K 10-Q · filed 2019-10-23 | $463.00K derived: sum of 2 quarters · filed 2019-10-23 | $126.00K derived: sum of 3 quarters · filed 2019-10-23 | |
| 2018-06-30 | $149.00K 10-Q · filed 2019-10-23 | -$188.00K derived: sum of 2 quarters · filed 2019-10-23 | ||
| 2018-03-31 | -$337.00K 10-Q · filed 2019-10-23 | |||
| 2017-12-31 | -$518.00K 10-K · filed 2019-02-15 | |||
| 2016-12-31 | $521.00K 10-K · filed 2019-02-15 | |||
| 2015-12-31 | -$659.00K 10-K · filed 2018-02-16 | |||
| 2014-12-31 | -$13.71M 10-K · filed 2017-02-17 | |||
| 2013-12-31 | $13.09M 10-K · filed 2016-02-25 | |||
| 2013-03-31 | $703.00K 10-KT · filed 2014-02-27 | |||
| 2012-03-31 | $627.00K 10-KT · filed 2014-02-27 | |||
| 2011-03-31 | $379.00K 10-K · filed 2013-05-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |